Amsterdam Gastroenterology and Metabolism, Department of Gastroenterology and Hepatology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
Department of Epidemiology and Biostatistics, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
Clin Gastroenterol Hepatol. 2019 Apr;17(5):940-947.e2. doi: 10.1016/j.cgh.2018.09.046. Epub 2018 Oct 3.
BACKGROUND & AIMS: There have been few reproducible studies of mortality in patients with autoimmune hepatitis (AIH) and its variants. We calculated mortality in a large national cohort of patients with AIH, with vs without cirrhosis, in the Netherlands.
We collected data from 449 patients with established AIH (77% female), from 6 academic and 10 non-academic hospitals in the Netherlands. We identified 29 patients with AIH and primary biliary cholangitis and 35 patients with AIH and primary sclerosing cholangitis (AIH-PSC). Mortality and liver transplantation data were assessed from August 1, 2006 through July 31, 2016. Standardized mortality ratios (SMR) were calculated using age-, sex-, and calendar year-matched mortality for the general Dutch population.
During the 10-year follow-up period, 60 patients (13%) died (mean age, 71 years; range, 33-94 years). Twenty-six causes of death were liver related (43%), whereas the others could not be attributed to liver disease. Patients with AIH and cirrhosis had significantly higher mortality than the general population (SMR, 1.9; 95% CI, 1.2-3.4), whereas patients without cirrhosis did not (SMR, 1.2; 95% CI, 0.8-1.8). Patients with AIH-PSC had the largest increase in mortality, compared to the general population (SMR, 4.7; 95% CI, 1.5-14.6), of all groups analyzed. Mortality in patients with AIH and primary biliary cholangitis was not greater than the general population. Four or more relapses per decade or not achieving remission was associated with an increase in liver-related death or liver transplantation. Nine patients underwent liver transplantation; 2 died from non-liver related causes. Four of 9 patients on the waitlist for transplantation died before receiving a donated liver.
In an analysis of data from a large national cohort of patients with AIH, we found increased mortality of patients with cirrhosis, but not of patients without cirrhosis, compared to the general Dutch population. Survival was significantly reduced in patients with AIH and features of concurrent PSC.
自身免疫性肝炎(AIH)及其变异患者的死亡率鲜有可重复的研究。我们在荷兰的一个大型全国性 AIH 患者队列中计算了有或无肝硬化的 AIH 患者的死亡率。
我们从荷兰 6 家学术医院和 10 家非学术医院的 449 名确诊 AIH 患者(77%为女性)中收集数据。我们确定了 29 例 AIH 合并原发性胆汁性胆管炎和 35 例 AIH 合并原发性硬化性胆管炎(AIH-PSC)患者。从 2006 年 8 月 1 日至 2016 年 7 月 31 日评估死亡率和肝移植数据。使用与荷兰一般人群年龄、性别和日历年份匹配的死亡率计算标准化死亡率比(SMR)。
在 10 年的随访期间,60 名患者(13%)死亡(平均年龄 71 岁;范围 33-94 岁)。26 例死因与肝脏相关(43%),而其他死因与肝脏疾病无关。有肝硬化的 AIH 患者的死亡率明显高于一般人群(SMR 为 1.9;95%CI 为 1.2-3.4),而无肝硬化的患者则没有(SMR 为 1.2;95%CI 为 0.8-1.8)。与所有分析的组相比,AIH-PSC 患者的死亡率增加幅度最大,与一般人群相比(SMR 为 4.7;95%CI 为 1.5-14.6)。AIH 合并原发性胆汁性胆管炎患者的死亡率并未高于一般人群。每十年发生 4 次或更多次复发或未缓解与肝脏相关死亡或肝移植的增加有关。9 名患者接受了肝移植;其中 2 人死于非肝脏相关原因。9 名等待移植患者中有 4 人在接受供肝前死亡。
在对一个大型全国性 AIH 患者队列的数据进行分析时,我们发现与荷兰一般人群相比,肝硬化患者的死亡率增加,但无肝硬化患者的死亡率没有增加。具有并发 PSC 特征的 AIH 患者的生存显著降低。